EP1082459A1 - Neue methode zur diagnose, überwachung und bestimmung des stadiums von lungenkrebs - Google Patents

Neue methode zur diagnose, überwachung und bestimmung des stadiums von lungenkrebs

Info

Publication number
EP1082459A1
EP1082459A1 EP99921894A EP99921894A EP1082459A1 EP 1082459 A1 EP1082459 A1 EP 1082459A1 EP 99921894 A EP99921894 A EP 99921894A EP 99921894 A EP99921894 A EP 99921894A EP 1082459 A1 EP1082459 A1 EP 1082459A1
Authority
EP
European Patent Office
Prior art keywords
lsg
levels
cancer
patient
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921894A
Other languages
English (en)
French (fr)
Other versions
EP1082459A4 (de
Inventor
Fei Yang
Roberto A. Macina
Yongming Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1082459A1 publication Critical patent/EP1082459A1/de
Publication of EP1082459A4 publication Critical patent/EP1082459A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Definitions

  • a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.
  • Lngl07 being a diagnostic marker for lung cancer.
  • the amino acid sequence encoded by Lngl07 is depicted in SEQ ID NO: 9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP99921894A 1998-05-21 1999-05-12 Neue methode zur diagnose, überwachung und bestimmung des stadiums von lungenkrebs Withdrawn EP1082459A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8621298P 1998-05-21 1998-05-21
US86212P 1998-05-21
PCT/US1999/010344 WO1999060160A1 (en) 1998-05-21 1999-05-12 A novel method of diagnosing, monitoring, and staging lung cancer

Publications (2)

Publication Number Publication Date
EP1082459A1 true EP1082459A1 (de) 2001-03-14
EP1082459A4 EP1082459A4 (de) 2002-09-25

Family

ID=22197037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921894A Withdrawn EP1082459A4 (de) 1998-05-21 1999-05-12 Neue methode zur diagnose, überwachung und bestimmung des stadiums von lungenkrebs

Country Status (4)

Country Link
EP (1) EP1082459A4 (de)
JP (1) JP3688585B2 (de)
CA (1) CA2328138A1 (de)
WO (1) WO1999060160A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
WO2000008206A1 (en) * 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US20020004206A1 (en) * 1999-04-09 2002-01-10 Berger Barry M. Methods of screening for disease
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001053349A2 (en) * 2000-01-21 2001-07-26 Ludwig Institute For Cancer Research Small cell lung cancer associated antigens and uses therefor
WO2001061055A2 (en) * 2000-02-17 2001-08-23 Diadexus, Inc. Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
AU2001251084A1 (en) * 2000-03-29 2001-10-08 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
US20030022257A1 (en) * 2000-07-21 2003-01-30 Macina Roberto A. Compositions and methods relating to lung specific genes
WO2002018576A2 (en) * 2000-08-28 2002-03-07 Diadexus, Inc. Compositions and methods relating to lung specific genes
WO2002077236A2 (en) * 2000-10-26 2002-10-03 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2002068633A2 (en) * 2000-11-22 2002-09-06 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
EP1873245A1 (de) * 2001-02-28 2008-01-02 Genentech, Inc. Interleukin-8-homologe Polypeptide und ihre therapeutische Verwendung
ATE449187T1 (de) * 2001-08-16 2009-12-15 Us Health Molekulare eigenschaften von nichtkleinzelligem lungenkrebs
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006013012A2 (en) * 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
EP3770278A1 (de) 2005-04-14 2021-01-27 The Trustees of Boston University Diagnose für lungenerkrankungen mittels klassenvorhersage
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
JP2009529329A (ja) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法
WO2009039457A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN107206043A (zh) 2014-11-05 2017-09-26 维拉赛特股份有限公司 使用机器学习和高维转录数据在经支气管活检上诊断特发性肺纤维化的系统和方法
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039419A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO2000000610A2 (en) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020143A1 (en) * 1996-11-05 1998-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
JP2001522225A (ja) * 1997-01-31 2001-11-13 アボツト・ラボラトリーズ 肺の疾患の検出に有用な試薬及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039419A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO2000000610A2 (en) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] March 1998 (1998-03) WANG Z ET AL: "ÄExpression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes]" Database accession no. NLM11263354 XP002206076 & ZHONGHUA JIE HE HE HU XI ZA ZHI = CHINESE JOURNAL OF TUBERCULOSIS AND RESPIRATORY DISEASES. CHINA MAR 1998, vol. 21, no. 3, March 1998 (1998-03), pages 164-166, ISSN: 1001-0939 *
See also references of WO9960160A1 *

Also Published As

Publication number Publication date
JP3688585B2 (ja) 2005-08-31
WO1999060160A1 (en) 1999-11-25
JP2002515262A (ja) 2002-05-28
EP1082459A4 (de) 2002-09-25
CA2328138A1 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
WO1999060160A1 (en) A novel method of diagnosing, monitoring, and staging lung cancer
CN107326066B (zh) 用于膀胱癌检测的尿标记物
EP2430193B1 (de) Marker für den nachweis von magenkrebs
EP1080227B1 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
CA2322023A1 (en) A novel method of detecting and monitoring endometrial and uterine cancers
JP3524061B2 (ja) 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法
JP3677210B2 (ja) 前立腺がんを診断し、モニターし、そして病期決定する新規な方法
JP2002525031A (ja) 大腸癌の診断、監視、病期決定、画像処理及び治療の新規方法
US7713693B1 (en) Human cancer cell specific gene transcript
US6949339B1 (en) Method of diagnosing, monitoring, and staging colon cancer
US20100167278A1 (en) Novel Method of Diagnosing, Monitoring, and Staging Prostate Cancer
US7160679B1 (en) Method of diagnosing, monitoring, and staging lung cancer
AU2020200168A1 (en) Urine markers for detection of bladder cancer
JP2020072705A (ja) 膀胱癌を検出するための尿マーカー
JP2002526760A (ja) 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法
AU2015200982A1 (en) Urine markers for detection of bladder cancer
US20220064235A1 (en) Urine Markers and Methods for Detection of Bladder Cancer and Treatment Thereof
EP1621639A2 (de) Neuartiges Verfahren zur Diagnose, zur Überwachung und Verlaufsbeobachtung von Prostatakrebs
KR20230119346A (ko) 흑색종 치료 내성 예측용 trim51 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7G 01N 33/72 B, 7G 01N 33/574 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020809

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050504